CytomX Therapeutics (CTMX) Earnings Date, Estimates & Call Transcripts $1.13 +0.06 (+5.61%) (As of 05:22 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CytomX Therapeutics Latest Earnings SummaryActual EPS (Nov. 7) $0.07 Beat By $0.23 Consensus EPS (Nov. 7) -$0.16 CytomX Therapeutics issued Q3 2024 earnings on November 7, 2024, reporting an EPS of $0.07, which topped the consensus estimate of -$0.16 by $0.23. Quarterly revenue was reported to be $33.43 million, above analysts' expectations of $18.92 million. With a trailing EPS of $0.17 and a P/E Ratio of 6.65, CytomX Therapeutics' earnings are expected to decrease next year, from ($0.05) to ($0.33) per share. Conference CallConference Call TranscriptPowered by Get CytomX Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytomX Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCTMX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CTMX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. CytomX Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.20$0.02-$0.09Q2 20242$0.01$0.16$0.09Q3 20242$0.01$0.15$0.08Q4 20242-$0.19-$0.01-$0.10FY 20248-$0.37$0.32-$0.03Q1 20251-$0.02-$0.02-$0.02Q2 20251-$0.03-$0.03-$0.03Q3 20251-$0.03-$0.03-$0.03Q4 20251-$0.04-$0.04-$0.04FY 20254($0.12)($0.12)($0.12) CytomX Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/7/2024Q3 2024-$0.16$0.07+$0.23$0.07$18.92M$33.43M8/8/2024Q2 2024-$0.07-$0.08 -$0.01-$0.08$21.79M$25.12M5/8/2024Q1 2024-$0.06$0.17+$0.23$0.17$23.40M$41.46M3/11/2024Q4 2023$0.02$0.01 -$0.01$0.01$23.36M$26.61M11/7/2023Q3 2023-$0.17$0.04+$0.21$0.04$17.38M$26.38M8/8/2023Q2 2023-$0.19-$0.02+$0.17-$0.02$17.38M$24.72M Get the Latest News and Ratings for CTMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/9/2023Q1 2023-$0.16-$0.05+$0.11-$0.05$22.25M$23.50M3/27/2023Q4 2022-$0.21-$0.42 -$0.21-$0.42$17.71M$0.95M CytomX Therapeutics Earnings - Frequently Asked Questions When did CytomX Therapeutics announce their last quarterly earnings? CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earning data on Thursday, November 7, 2024. Learn more on CTMX's earnings history. Did CytomX Therapeutics beat their earnings estimates last quarter? In the previous quarter, CytomX Therapeutics (NASDAQ:CTMX) reported $0.07 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.23. Learn more on analysts' earnings estimate vs. CTMX's actual earnings. How can I listen to CytomX Therapeutics's earnings conference call? The conference call for CytomX Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read CytomX Therapeutics's conference call transcript? The conference call transcript for CytomX Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does CytomX Therapeutics generate each year? CytomX Therapeutics (NASDAQ:CTMX) has a recorded annual revenue of $126.62 million. How much profit does CytomX Therapeutics generate each year? CytomX Therapeutics (NASDAQ:CTMX) has a recorded net income of -$570,000.00. CTMX has generated $0.17 earnings per share over the last four quarters. What is CytomX Therapeutics's price-to-earnings ratio? CytomX Therapeutics (NASDAQ:CTMX) has a trailing price-to-earnings ratio of 6.65. What is CytomX Therapeutics's EPS forecast for next year? CytomX Therapeutics's earnings are expected to decrease from ($0.05) per share to ($0.33) per share in the next year. More Earnings Resources from MarketBeat Related Companies NGNE Earnings Date ETON Earnings Date AQST Earnings Date JSPR Earnings Date VALN Earnings Date BTMD Earnings Date SLRN Earnings Date VYGR Earnings Date CGC Earnings Date TRVI Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report Forced out of retirement by these trades (Ad)You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedMake sure to check out Gamma Pockets HERE while it’s still widely available This page (NASDAQ:CTMX) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
